RecruitingOsteoarthritisOverweight or Obesity

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Eligible age

18+ yrs

Accepts

All genders

Locations

19 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.

Sponsor: Eli Lilly and Company

You may qualify if…

✓ Have a body mass index (BMI) of 27 kilograms per square meter (kg/m²) or higher at screening
✓ Have a stable body weight (less than 5% body weight change) for 90 days prior to screening
✓ Have tried at least once to lose weight through diet but were unsuccessful
✓ Have osteoarthritis of the knee and at least one of the following conditions:
✓ Be over 50 years old
✓ Have morning knee stiffness that lasts about 30 minutes
✓ Have a crackling or grinding sound or feeling in the knee

You may not qualify if…

✕ Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed greater than 1 year before screening)
✕ Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
✕ Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
✕ Have an active knee infection
✕ Have had within 90 days prior to screening:
✕ heart attack
✕ stroke
✕ coronary artery revascularization